BRAF and neoplasm: More than half of the melanoma tumors harbor an activating mutation in BRAF, a serine/threonine kinase protein, which enhances tumor proliferation and invasion, hence targeted BRAF inhibitor therapies such as Vemurafenib have been developed with high efficacy [89].